vs
アボット（ABT）とEncompass Health Corp（EHC）の財務データ比較。上の社名をクリックして会社を切り替えられます
アボットの直近四半期売上が大きい（$11.5B vs $1.5B、Encompass Health Corpの約7.4倍）。アボットの純利益率が高く（15.5% vs 9.5%、差は6.0%）。Encompass Health Corpの前年同期比売上増加率が高い（9.9% vs 4.4%）。アボットの直近四半期フリーキャッシュフローが多い（$2.6B vs $116.7M）。過去8四半期でEncompass Health Corpの売上複合成長率が高い（8.3% vs 7.2%）
アボットは米国イリノイ州アボットパークに本社を置く多国籍医療ヘルスケア企業です。米国外向けの医薬品、診断製品、栄養製品、医療機器の開発・製造・販売を事業の柱とし、世界各国の人々の健康をサポートしています。
エンコンパスヘルスコーポレーション（旧Amcare、HealthSouth）は米国アラバマ州バーミンガムに本社を置く米国最大の入院リハビリサービス事業者で、39州とプエルトリコに173の入院リハビリ病院を展開し、脳卒中や神経疾患、心肺疾患、脳損傷から回復中の患者に専門的な治療とケアを提供している。
ABT vs EHC — 直接比較
損益計算書 — Q4 2025 vs Q4 2025
| 指標 | | |
|---|---|---|
| 売上 | $11.5B | $1.5B |
| 純利益 | $1.8B | $146.1M |
| 粗利率 | 57.0% | — |
| 営業利益率 | 19.6% | 16.7% |
| 純利益率 | 15.5% | 9.5% |
| 売上前年比 | 4.4% | 9.9% |
| 純利益前年比 | -80.8% | 20.8% |
| EPS（希薄化後） | $1.01 | $1.43 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $11.5B | $1.5B | ||
| Q3 25 | $11.4B | $1.5B | ||
| Q2 25 | $11.1B | $1.5B | ||
| Q1 25 | $10.4B | $1.5B | ||
| Q4 24 | $11.0B | $1.4B | ||
| Q3 24 | $10.6B | $1.4B | ||
| Q2 24 | $10.4B | $1.3B | ||
| Q1 24 | $10.0B | $1.3B |
| Q4 25 | $1.8B | $146.1M | ||
| Q3 25 | $1.6B | $126.5M | ||
| Q2 25 | $1.8B | $142.1M | ||
| Q1 25 | $1.3B | $151.5M | ||
| Q4 24 | $9.2B | $120.9M | ||
| Q3 24 | $1.6B | $108.2M | ||
| Q2 24 | $1.3B | $114.1M | ||
| Q1 24 | $1.2B | $112.5M |
| Q4 25 | 57.0% | — | ||
| Q3 25 | 55.4% | — | ||
| Q2 25 | 56.4% | — | ||
| Q1 25 | 56.9% | — | ||
| Q4 24 | 55.0% | — | ||
| Q3 24 | 55.8% | — | ||
| Q2 24 | 55.6% | — | ||
| Q1 24 | 55.2% | — |
| Q4 25 | 19.6% | 16.7% | ||
| Q3 25 | 18.1% | 14.9% | ||
| Q2 25 | 18.4% | 16.2% | ||
| Q1 25 | 16.3% | 16.4% | ||
| Q4 24 | 17.4% | 14.3% | ||
| Q3 24 | 17.5% | 13.6% | ||
| Q2 24 | 16.1% | 14.3% | ||
| Q1 24 | 13.9% | 13.6% |
| Q4 25 | 15.5% | 9.5% | ||
| Q3 25 | 14.5% | 8.6% | ||
| Q2 25 | 16.0% | 9.7% | ||
| Q1 25 | 12.8% | 10.4% | ||
| Q4 24 | 84.1% | 8.6% | ||
| Q3 24 | 15.5% | 8.0% | ||
| Q2 24 | 12.5% | 8.8% | ||
| Q1 24 | 12.3% | 8.5% |
| Q4 25 | $1.01 | $1.43 | ||
| Q3 25 | $0.94 | $1.24 | ||
| Q2 25 | $1.01 | $1.39 | ||
| Q1 25 | $0.76 | $1.48 | ||
| Q4 24 | $5.26 | $1.18 | ||
| Q3 24 | $0.94 | $1.06 | ||
| Q2 24 | $0.74 | $1.12 | ||
| Q1 24 | $0.70 | $1.10 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $8.9B | $72.2M |
| 総負債低いほど良い | $12.9B | $2.4B |
| 株主資本純資産 | $52.1B | $2.4B |
| 総資産 | $86.7B | $7.1B |
| 負債/資本比率低いほどレバレッジが低い | 0.25× | 1.00× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $8.9B | $72.2M | ||
| Q3 25 | $7.7B | $48.7M | ||
| Q2 25 | $7.3B | $99.1M | ||
| Q1 25 | $6.8B | $95.8M | ||
| Q4 24 | $8.0B | $85.4M | ||
| Q3 24 | $7.8B | $147.8M | ||
| Q2 24 | $7.2B | $154.4M | ||
| Q1 24 | $6.7B | $134.4M |
| Q4 25 | $12.9B | $2.4B | ||
| Q3 25 | — | $2.4B | ||
| Q2 25 | — | $2.3B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | $14.1B | $2.4B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | — | $2.7B | ||
| Q1 24 | — | $2.7B |
| Q4 25 | $52.1B | $2.4B | ||
| Q3 25 | $51.0B | $2.4B | ||
| Q2 25 | $50.6B | $2.3B | ||
| Q1 25 | $48.8B | $2.2B | ||
| Q4 24 | $47.7B | $2.1B | ||
| Q3 24 | $39.8B | $2.0B | ||
| Q2 24 | $39.3B | $1.8B | ||
| Q1 24 | $38.8B | $1.7B |
| Q4 25 | $86.7B | $7.1B | ||
| Q3 25 | $84.2B | $6.9B | ||
| Q2 25 | $84.0B | $6.8B | ||
| Q1 25 | $81.4B | $6.6B | ||
| Q4 24 | $81.4B | $6.5B | ||
| Q3 24 | $74.4B | $6.5B | ||
| Q2 24 | $73.0B | $6.4B | ||
| Q1 24 | $72.5B | $6.2B |
| Q4 25 | 0.25× | 1.00× | ||
| Q3 25 | — | 1.01× | ||
| Q2 25 | — | 1.02× | ||
| Q1 25 | — | 1.08× | ||
| Q4 24 | 0.30× | 1.14× | ||
| Q3 24 | — | 1.20× | ||
| Q2 24 | — | 1.46× | ||
| Q1 24 | — | 1.54× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $3.3B | $346.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $2.6B | $116.7M |
| FCFマージンFCF / 売上 | 22.9% | 7.6% |
| 設備投資強度設備投資 / 売上 | 6.0% | 14.8% |
| キャッシュ転換率営業CF / 純利益 | 1.87× | 2.37× |
| 直近12ヶ月FCF直近4四半期 | $7.4B | $439.2M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $3.3B | $346.0M | ||
| Q3 25 | $2.8B | $270.8M | ||
| Q2 25 | $2.0B | $270.2M | ||
| Q1 25 | $1.4B | $288.6M | ||
| Q4 24 | $2.9B | $278.8M | ||
| Q3 24 | $2.7B | $267.8M | ||
| Q2 24 | $2.0B | $217.4M | ||
| Q1 24 | $1.0B | $238.8M |
| Q4 25 | $2.6B | $116.7M | ||
| Q3 25 | $2.3B | $83.7M | ||
| Q2 25 | $1.5B | $113.3M | ||
| Q1 25 | $933.0M | $125.5M | ||
| Q4 24 | $2.1B | $80.1M | ||
| Q3 24 | $2.1B | $120.3M | ||
| Q2 24 | $1.4B | $60.5M | ||
| Q1 24 | $627.0M | $99.4M |
| Q4 25 | 22.9% | 7.6% | ||
| Q3 25 | 20.2% | 5.7% | ||
| Q2 25 | 13.9% | 7.8% | ||
| Q1 25 | 9.0% | 8.6% | ||
| Q4 24 | 19.6% | 5.7% | ||
| Q3 24 | 20.2% | 8.9% | ||
| Q2 24 | 13.8% | 4.6% | ||
| Q1 24 | 6.3% | 7.6% |
| Q4 25 | 6.0% | 14.8% | ||
| Q3 25 | 4.4% | 12.7% | ||
| Q2 25 | 4.5% | 10.8% | ||
| Q1 25 | 4.7% | 11.2% | ||
| Q4 24 | 6.6% | 14.1% | ||
| Q3 24 | 5.2% | 10.9% | ||
| Q2 24 | 5.1% | 12.1% | ||
| Q1 24 | 4.0% | 10.6% |
| Q4 25 | 1.87× | 2.37× | ||
| Q3 25 | 1.70× | 2.14× | ||
| Q2 25 | 1.15× | 1.90× | ||
| Q1 25 | 1.07× | 1.90× | ||
| Q4 24 | 0.31× | 2.31× | ||
| Q3 24 | 1.64× | 2.48× | ||
| Q2 24 | 1.51× | 1.91× | ||
| Q1 24 | 0.84× | 2.12× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ABT
セグメントデータなし
EHC
| Medicare | $1.0B | 66% |
| Medicare Advantage | $243.1M | 16% |
| Managed Care | $160.7M | 10% |
| Medicaid | $47.0M | 3% |
| Other Income Source | $44.8M | 3% |
| Other Thirdparty Payors | $11.2M | 1% |
| Workers Compensation | $7.6M | 0% |
| Patients | $4.6M | 0% |
